Sanofi

Clinical Study Results Medicines, including Rare Diseases

Important

Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country. In the event that the product is described as no longer a Sanofi product, reasons could include that the product was transferred to another company.

This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

Filter by:

And

1248 result(s) found
Generic NameTrade NameCondition(s)Study CodeStudy NameAccess to Study / ProtocolAccess to Results
CLOPIDOGREL
Plavix
Coronary Syndrome, Acute
EFC6720 (DV7314-26)NANCT00325390Summary
CLOPIDOGREL
Plavix
Cardiovascular Diseases
L_8564NANCT00648453Summary
CLOPIDOGREL
Plavix
Thrombosis
L_9317CASTLENCT00716924Summary
CLOPIDOGREL
Plavix
Metabolic Syndrome
L_9842PROCLAIMNCT00296803Summary
CLOPIDOGREL
Plavix
Heart Defect, Congenital
LTS10916CLARINET LTNCT00833703Tabulated Results
CLOPIDOGREL
Plavix
Angina, Stable Myocardial Infarction
PDY4422PICOLONCT00115375Summary
CLOPIDOGREL
Plavix
Peripheral Arterial Disease
SFY10810NANCT00862420Summary
CLOPIDOGREL
Plavix
Cerebral infarction
SFY6913NANCT00386191Summary
CRF1 ANTAGONIST
Not marketed
Depression
DFI5687AGATEEudraCT: 2009-010339-42Summary Results
DOCETAXEL
Taxotere
Prostate Cancer, Hormone Refractory
ARD6562 (XRP6976J/2101)NANCT00291005Summary

References:

* These study results were previously posted on GenzymeClinicalResearch.com
** This link replaces the same summary that was previously posted